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DOI 10.1016/j.ccr.2011.01.001SUMMARYThe full scale of human miRNome in specific cell or tissue, especially in cancers, remains to be determined.
An in-depth analysis of miRNomes in human normal liver, hepatitis liver, and hepatocellular carcinoma (HCC)
was carried out in this study. We found nine miRNAs accounted for 88.2% of the miRNome in human liver.
The third most highly expressed miR-199a/b-3p is consistently decreased in HCC, and its decrement
significantly correlates with poor survival of HCC patients. Moreover, miR-199a/b-3p can target tumor-
promoting PAK4 to suppress HCC growth through inhibiting PAK4/Raf/MEK/ERK pathway both in vitro
and in vivo. Our study provides miRNomes of human liver and HCC and contributes to better understanding
of the important deregulated miRNAs in HCC and liver diseases.INTRODUCTION
MicroRNAs (miRNAs) inhibit translation or induce mRNA degra-
dation in general by binding to the 30 untranslational region (30
UTR) of target mRNAs. Since initial observation, about 1000
human miRNAs have been registered in miRBase (v.14.0) (Grif-
fiths-Jones et al., 2006). Although a previous classical approach
of cloning has partially revealed miRNA expression profile in
a panel of mammalian tissues and cell types (Landgraf et al.,
2007; Basso et al., 2009), low throughput with low sensitivity
and poor resolution makes these approaches unlikely to define
miRNome. Massively parallel signature sequencing (MPSS) ofSignificance
The full-scale analysis of miRNomes in human normal liver, hep
the third most abundant miRNA in the liver, might be an import
sion strongly correlates with the markedly reduced survival o
subcutaneous and orthotopic human HCC-bearing mouse m
The miRNomes of human normal liver, hepatitis liver, and HCC
in liver biology and liver diseases.
232 Cancer Cell 19, 232–243, February 15, 2011 ª2011 Elsevier Inc.miRNAs can identify miRNome in-depth, which reveals miRNA
expression differences as well as the individual miRNA abun-
dance. As a minimum threshold amount must be reached for
miRNAs to repress target mRNAs (Brown et al., 2007; Sarasin-
Filipowicz et al., 2009), the abundance of miRNAs and their ratios
in the entire miRNome of specific cell or tissue may be more
important for their functions.
Infection of hepatitis B Virus (HBV) or hepatitis C Virus (HCV) in
human liver induces the development of chronic hepatitis, liver
cirrhosis, and in some instances hepatocellular carcinoma
(HCC). HCC is among the leading causes of cancer-related
deaths in Asia, especially in China. Previous reports suggestedatitis liver, and HCC led us to conclude that miR-199a/b-3p,
ant deregulated miRNA in HCC. LowmiR-199a/b-3p expres-
f HCC patients. AAV8-mediated in vivo gene delivery in the
odels demonstrate miR-199a/b-3p’s therapeutic potential.
may present a resource for researching the roles of miRNAs
Table 1. Most Abundantly Expressed miRNAs in Human Normal Liver
miRNA
TPM in Normal
Liver Sample 1
TPM in Normal
Liver Sample 2
TPM in Normal
Liver Sample 3
Average TPM
in Normal Liver
Average Ratio
in miRNome
miR-122 529,834 508,274 522,504 520,204 52.0%
miR-192 176,591 170,585 160,383 169,186 16.9%
miR-199a/b-3p 45,033 49,702 51,920 48,885 4.9%
miR-101 33,431 37,296 39,285 36,671 3.7%
let-7a 29,899 34,474 33,908 32,760 3.3%
miR-99a 22,430 22,756 20,583 21,923 2.2%
let-7c 18,848 21,356 23,870 21,358 2.1%
let-7b 16,255 19,960 13,938 16,718 1.7%
let-7f 13,786 13,888 16,598 14,757 1.5%
Total 886,107 878,291 882,989 882,462 88.2%
TPM, transcripts per million. See also Table S1.
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miRNomes in Human Liver and HCCsome deregulated miRNAs in HCC but none of them was based
on deep sequencing (Gramantieri et al., 2007, 2008, 2009;
Braconi and Patel, 2008; Ji et al., 2009a, 2009b; Ladeiro et al.,
2008; Varnholt et al., 2008; Wang et al., 2008, 2009a; Wong
et al., 2008; Murakami et al., 2006; Kutay et al., 2006; Budhu
et al., 2008; Ura et al., 2009; Coulouarn et al., 2009; Xiong
et al., 2010). The abundance of these deregulated miRNAs
remains unknown to date. The results obtained from only
microarray or real-time quantitative RT-PCR (qRT-PCR) might
be controversial and complicated. Therefore, identification of
miRNomes in human normal liver tissue, HBV or HCV-infected
liver tissues and HCC in-depth may reveal the important deregu-
lated miRNAs in HCC.
RESULTS
miRNomes in Human Normal Liver, Hepatitis Liver,
and HCC
We applied MPSS to carry out an in-depth analysis of the
miRNomes in three normal liver tissues (distal normal liver tissue
of liver hemangioma), an HBV-infected liver, a severe chronic
hepatitis B liver, two HBV-related HCCs, an HCV-related HCC,
and an HCC without HBV or HCV infection. Clean sequenced
reads were used for further analysis (see Experimental Proce-
dures; see Table S1 available online). The abundance value of
each known miRNA was normalized using ‘‘transcripts per
million (TPM)’’ in each small RNA library. Except for HCC, the
known miRNAs exhibited a similar distribution in each library
based on classification of TPM degrees. In normal liver tissue,
85.9% miRNAs were poorly expressed (<10 TPM), 13.2%
miRNAs were expressed modestly (10–10,000 TPM), and only
0.9% (9) miRNAs were expressed abundantly (>10,000 TPM)
but they accounted for 88.2% of all miRNA reads (Table 1).
The three most abundantly expressed miRNAs were miR-122,
miR-192, and miR-199a/b-3p, accounting for 52.0%,
16.9%, and 4.9% of the miRNome, respectively.
Deregulated Abundant miRNAs in HCC
Which miRNA, especially those unreported before, is the major
player in HCC pathogenesis? As only a few miRNAs are abun-
dantly expressed in the miRNome and they seem to be the
most important in liver biology and HCC, only miRNAs withCTPM >2000 (accounting for 99% of the miRNome) and more
than 1-fold alteration were considered most likely to be impor-
tant in HCC pathogenesis in this study (Table 2; Tables S2 and
S3). miR-199a/b-3p was markedly decreased in all the
sequenced HCC samples as compared with matched nonneo-
plastic liver tissues. We also sequenced different regions of non-
neoplastic liver tissues to confirm their reliability and found their
miRNomes similar (Table S2).
The deregulated abundant miRNAs in HCC were further
confirmed by qRT-PCR in 40HBV-related HCC, five HCV-related
HCC, and three HCC of other etiologies (Table S4). The ratio of
HCC samples with more than 1-fold increment or decrement of
the individual miRNAwas shown in Table 3 and Table S5. Among
these abundant miRNAs, miR-199a/b-3p expression was the
most consistently and markedly decreased. However, many
previously reported deregulated miRNAs in HCC were found to
be expressed at relatively low levels which might make them
less important in HCC pathogenesis (Table S6), and some of
them seemed unchanged in the sequencing data. Also, expres-
sion of abundant miR-122 and let-7 members were less consis-
tently decreased in HCC samples (Table 3). Interestingly, no
significant difference between miRNomes of HBV or HCV-in-
fected liver tissues and normal liver tissue was found (Table 2;
Table S2). Additionally, some miRNAs, poorly expressed but
markedly altered in the sequenced HCC samples, were
confirmed by qRT-PCR, and they were also less consistently
deregulated (Table S7). Together, the miRNomes of human
normal liver, hepatitis liver and HCC led us to identify the consis-
tently deregulated miRNA in HCC.
To further investigate whether the deregulated abundant
miRNAs correlate with the survival of HCC patients, we investi-
gated two independent cohorts of HCC patients, Cohort 1 of
142 patients and Cohort 2 of 152 patients (Table S8). As
compared with the matched nonneoplastic tissue of each HCC
sample, miR-199a/b-3p level decreased in 88% (125/142,
Cohort 1) and 86% (130/152, Cohort 2) of the HCC samples
while miR-122 level decreased in 46% (66/142, Cohort 1) and
47% (72/152, Cohort 2) of them. Kaplan-Meier analysis
revealed that low miR-199a/b-3p level in HCC tissues signifi-
cantly correlated with the markedly reduced tumor-free survival
and overall survival of HCC patients (Figure 1), suggesting the
important roles of miR-199a/b-3p in pathogenesis of HCC andancer Cell 19, 232–243, February 15, 2011 ª2011 Elsevier Inc. 233
Table 2. Most Abundantly Expressed miRNAs in HCC and Matched Nonneoplastic Liver Tissues
miRNA
Average in
Normal Liver
HBV(+)
Adjacent
Sample 1
HBV(+)
HCC Sample 1
HBV(+)
Adjacent
Sample 2
HBV(+)
HCC Sample 2
HCV(+)
Adjacent
HCV(+)
HCC
HBV(-) HCV(-)
Adjacent Tissue
HBV(-) HCV(-)
HCC
miR-122a 520,204 497,436 581,733 478,691 516,360 449,921 511,457 597,746 17,280
miR-192a 169,186 184,230 182,858 153,346 205,819 111,731 166,201 111,530 164,532
199a/b-3pb 48,885 79,099 2588 58,199 2211 44,000 2831 39,779 2979
miR-101a 36,671 37,538 35,730 54,202 44,686 26,361 38,555 57,519 39,321
let-7a b 32,760 26,392 5515 39,339 40,747 36,908 28,419 26,423 110,611
miR-99ab 21,923 22,139 6019 27,594 10,326 20,701 6107 18,287 984
let-7cb 21,358 20,724 2930 19,340 15,231 18,996 17,059 19,840 1902
let-7bb 16,718 20,556 1531 11,819 2951 20,767 8864 12,944 19,074
let-7f a 14,757 12,778 10,047 14,195 12,139 14,230 14,552 19,600 133,023
let-7db 8792 5326 1264 8605 6390 9110 6471 6256 56,226
miR-100b 3606 4166 81 5959 7863 4763 7708 2742 998
125b-5pb 2665 2043 234 2634 992 1542 1391 1368 76
miR-143b 2269 2254 750 2635 996 6167 763 1278 4573
miR-29cb 2009 2067 670 2189 1062 3012 2301 3059 2266
miR-21c 5465 9561 16,241 10,099 12,314 9133 9356 10,948 82,662
miR-146bc 1614 698 7817 602 171 2737 643 597 555
miR-92ac 955 4775 16,142 874 420 2009 1650 1370 4269
Expressions of the abundant miRNAs seem.
a unaltered.
b decreased.
c increased in HCC. See also Tables S2 and S3.
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member expression in HCC tissues did not seem to significantly
correlate with the survival of HCC patients (Figure S1). Further-
more, in two other independent cohorts of HCC patients, Cohort
3 and Cohort 4, we validated that lowmiR-199a/b-3p level signif-
icantly correlated with the markedly reduced tumor-free survival
of HCC patients, but low miR-122 or let-7 member level did not
(Figure S1). Additionally, we performed Cox proportional
hazards regression analysis to exclude the confounder effect.
Univariate analysis was performed to identify factors which
might affect the tumor-free survival of HCC patients, followed
by multivariate analysis, which is controlled for potential
confounders. Significantly, in all the four independent HCC
cohorts, multivariate analysis confirmed that low miR-199a/
b-3p expression was an independent predictor for reduced
tumor-free survival of HCC patients (Table S9). Thus, these
results indicate the importance of miR-199a/b-3p expression in
human liver and HCC.Deregulated Histone Methylation Mediates Decrease
of miR-199a/b-3p Expression
As miR-199a/b-3p was found to be the consistently and mark-
edly decreased miRNA in HCC, we investigated the underlying
mechanism for the repression of miR-199a/b-3p in eight addi-
tional HCC samples (Table S10) in which miR-199a/b-3p level
decreased over 90% as compared with matched controls
(data not shown). miR-199a/b-3p is expressed from three
precursors in human genome: miR-199a-1 (Chromosome 19),
miR-199a-2 (Chromosome 1), and miR-199b (Chromosome 9),234 Cancer Cell 19, 232–243, February 15, 2011 ª2011 Elsevier Inc.sharing the same 3p mature miRNA. We first identified that
miR-199a/b-3p is mainly expressed frommiR-199a-2 by detect-
ing its precursors (Figure 2A; Figure S2A), and pri-miR-199a-2
expression is markedly decreased in HCC (Figure 2B), but pri-
miR-199b expression is not altered (data not shown). Second,
we ruled out the possibility that the three miR-199 genes were
deleted in HCC genome, as equal amounts of them were de-
tected in equal amounts of genomic DNA extracted from HCC
and matched controls using real-time PCR (data not shown).
Third, in the reported CpG islands known to regulate
miR-199a-1 and -2 expression (Kim et al., 2008), we found these
regions hypermethylated in both HCC and matched controls
through bisulfate sequencing (Figure S2B), thus indicating DNA
methylation is less likely to regulate their expression in the liver.
Fourth, as methylation of histone H3 at Lys4 (H3K4) is linked to
transcriptional activation, while methylation of H3 at K9 or K27
and of H4 at K20 is linked to transcriptional repression (Esteller,
2008), reported genomic regulatory regions (Kim et al., 2008)
(Figure 2C) of miR-199a-1 and -2 in HCC showed a reduced level
of H3K4 trimethylation (H3K4me3) but increased H3K9me3 and
H3K27me3 (Figure 2D), and the level of H4K20me3 was almost
equal to that of matched controls (data not shown). These results
indicate that reduced expression of miR-199a/b-3p in HCC is
mediated by histone modification and independent of DNA
methylation.miR-199a/b-3p Inhibits HCC Growth
We then investigated the pathophysiological significance, and its
underlying mechanisms, of the silenced miR-199a/b-3p in HCC.
Table 3. Confirmation of Deregulated miRNAs in 40 HBV-Related HCC Samples Compared with Matched Controls Using qRT-PCR
miRNA
Samples of Increased miRNA Expression Samples of Decreased miRNA Expression
Ratio of Increased
Samples
Average HCC/Control
in Increased Samples
Ratio of Decreased
Samples
Average HCC/Control
in Decreased Samples
miR-122 — — 18/40 (45%) 0.34 ± 0.09
miR-192 2/40 (5%) 2.57 ± 0.58 1/40 (3%) 0.39
miR-199a/b-3p — — 40/40 (100%) 0.12 ± 0.11
miR-99a — — 34/40 (85%) 0.15 ± 0.12
miR-125b-5p — — 33/40 (83%) 0.15 ± 0.12
miR-100 — — 31/40 (78%) 0.14 ± 0.11
miR-29c — — 28/40 (70%) 0.30 ± 0.10
miR-143 — — 26/40 (65%) 0.23 ± 0.13
let-7a — — 6/40 (15%) 0.36 ± 0.07
let-7b — — 13/40 (33%) 0.26 ± 0.11
let-7c — — 4/40 (10%) 0.36 ± 0.14
let-7d — — 3/40 (8%) 0.40 ± 0.12
miR-21 20/40 (50%) 4.76 ± 2.62 5/40 (13%) 0.41 ± 0.05
miR-92a 7/40 (18%) 3.07 ± 1.02 4/40 (10%) 0.37 ± 0.04
miR-146b 6/40 (15%) 12.9 ± 8.9 12/40 (30%) 0.31 ± 0.11
Data of HCC/control are shown as mean ± SD (n = samples with deregulated miRNA expression). See also Tables S4–S7.
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miRNomes in Human Liver and HCCThe silencing of miR-199a/b-3p prompted us to investigate
whether miR-199a/b-3p functions as a tumor suppressor in
HCC. In HCC cell lines Hep3B, SMMC-7721, Huh7, and
HepG2, miR-199a/b-3p expression was markedly decreased
comparedwith that in humannormal liver (Figure 3A; Figure S3A),
and transfection of miR-199a/b-3p restored its expression in
these cells (Figure 3B; Figure S3B). Restoration of miR-199a/b-
3p expression in HCC cell lines repressed cell growth (Figure 3C;
Figure S3C), induced cell apoptosis (Figure 3D), and inhibited
cell cycle progression, which might be G1-phase arrest (Fig-
ure 3E). Additionally, in miR-199a/b-3p stably overexpressed
Hep3B and SMMC-7721 cells, cell growth rate was also signifi-
cantly decreased compared with the control cells (Figures 3F
and 3G). These results demonstrate that miR-199a/b-3p may
function as a tumor suppressor in vitro.
In order to investigate the antitumor effect of miR-199a/b-3p
in vivo, we prepared a human HCC-bearing mouse model
SMMC-LTNM by transplanting histologically intact fresh human
HCC tissues to form subcutaneous transplantation tumor in
nudemice and then continuously maintained with subcutaneous
passage (Tao et al., 1998, 2007). The miRNA expression profile
of SMMC-LTNM tumor tissue is similar to that of freshly
isolated human HCC tissues, exhibiting equal expression of
miR-122 and miR-192 while silenced expression of miR-199a/
b-3p as compared with nonneoplastic human liver tissues
(Figure 4A). By intratumoral injection of cholesterol-conjugated
miR-199a/b-3p mimics (Wolfrum et al., 2007), we found that
miR-199a/b-3p expression in tumor was elevated (Figure 4A)
while tumor growth was inhibited, serum AFP was reduced,
and more significant tumor necrosis was observed (Figures 4B
and 4C). Thus, we conclude that restoration of miR-199a/b-3p
expression in HCC resulted in dramatic repression of HCC
growth.
In order to make the in vivo delivery of miR-199a/b-3p more
practical to target HCC, we constructed an adeno-associatedCvirus (AAV) 8 vector system encoding miR-199a/b-3p (AAV8-
miR-199a/b-3p) since AAV vectors have been suggested to be
promising for therapeutic gene delivery, particularly AAV8 for
liver-targeted gene therapy (McCarty, 2008; Kota et al., 2009).
Then, we evaluated the therapeutic potential of AAV8-mediated
gene delivery of miR-199a/b-3p in human HCC-bearing nude
mouse model SMMC-LTNM. Intratumoral injection of AAV8-
miR-199a/b-3p in SMMC-LTNM subcutaneous model elevated
miR-199a/b-3p expression in tumor (Figure 4D) while inhibited
tumor growth, reduced serum AFP, and caused more significant
tumor necrosis (Figures 4E and 4F). Importantly, miR-199a/b-3p
level was still higher in the liver of wild-type mice 2 months after
a single tail vein injection of 13 1012 vector genomes (vg) AAV8-
miR-199a/b-3p (Figure S4A). And in vivo administration of AAV8-
miR-199a/b-3p in wild-type mice did not seem to cause side
effects, as demonstrated by normal levels of endogenously
expressed abundant miRNAs in transduced liver (Figure S4B);
absence of any acute inflammation, fibrosis, or overt histological
evidence of toxicity (Figure S4C); and normal levels of serum
markers of liver function, such as ALT and AST (data not
shown). Most importantly, in SMMC-LTNM orthotopic model,
miR-199a/b-3p expression in tumor was also elevated while
tumor growth was inhibited and serum AFP was reduced upon
a single tail vein injection of 1 3 1012 vg AAV8-miR-199a/b-3p
(Figures 4G and 4H; Figure S4D). These data demonstrate that
AAV8 vector system provides an effective, nontoxic mean to
deliver miRNAs to the liver or HCC tissue, and in vivo administra-
tion of AAV8-miR-199a/b-3p may have considerable potential
for HCC gene therapy.
miR-199a/b-3p Targets PAK4
AsmiRNAs functionmainly through inhibition of target genes, the
target of miR-199a/b-3p that functions in HCC pathogenesis
was further analyzed. The hundreds of predicted target genes
in TargetScan (http://www.targetscan.org) were subjected toancer Cell 19, 232–243, February 15, 2011 ª2011 Elsevier Inc. 235
Figure 1. Low miR-199a/b-3p Expression
Correlates with Poor Survival of HCC
Patients
Shown are Kaplan-Meier survival curves of tumor-
free survival and overall survival in Cohort 1 (A) and
Cohort 2 (B) according to the ratio of miR-199a/
b-3p level in each tumor sample compared with
its matched nonneoplastic control, the median
value of this ratio in each cohort was chosen as
the cutoff point.
See also Figure S1, Tables S8, and S9.
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miRNomes in Human Liver and HCCenrichment analysis of cell signaling pathways using Kyoto
Encyclopedia of Genes and Genomes (KEGG) pathway data-
base (http://www.genome.jp/kegg/) (Hua et al., 2009). We found
that Mitogen-activated protein kinase (MAPK) signaling pathway
was the most significantly enriched by the predicted targets of
miR-199a/b-3p (p = 1.66 E-15) (Table S11 and Figure S5A). By
evaluating MAPK activation in miR-199a/b-3p overexpressed
HCC Hep3B cells, we found that extracellular signal-regulated
kinase (ERK) phosphorylation was inhibited (Figure 5A), while
p38 and c-Jun N-terminal kinase (JNK) phosphorylation were
not affected (data not shown). In the predicted targets partici-
pating in ERK activation, only PAK4, which is overexpressed in
various cancer cell lines but its contribution in HCC remains
elusive (Eswaran et al., 2009), contains two putative miR-199a/
b-3p target sites (Figure S5B). We found that expression of
a luciferase reporter containing 30 UTR of PAK4 was inhibited
by cotransfection with miR-199a/b-3p mimics (Figure 5B).
Furthermore, PAK4 protein expression was decreased by trans-
fection of miR-199a/b-3p mimics but increased by miR-199a/b-
3p inhibitors in Hep3B cells (Figures 5A and 5C). However, PAK4
mRNA level was not significantly influenced by overexpression
or inhibition of miR-199a/b-3p (data not shown), suggesting
that PAK4 expression could be inhibited by miR-199a/b-3p
mainly through translational inhibition. In available HCC protein
samples, we confirmed that PAK4 protein level was also
increased (Figure 5D), and PAK4 mRNA level was not signifi-
cantly altered (data not shown), further suggesting a posttran-
scriptional regulation of PAK4 in HCC. Together, these results236 Cancer Cell 19, 232–243, February 15, 2011 ª2011 Elsevier Inc.prove that endogenous PAK4 is targeted
and regulated by miR-199a/b-3p.
To identify the role of PAK4 in HCC
pathogenesis, we determined whether
inhibition of PAK4, just like miR-
199a/b-3p restoration, also resulted in
HCC repression. In HCC Hep3B and
SMMC-7721 cells, in vitro knockdown of
PAK4 repressed cell growth (Figure 5E;
Figure S5C), induced cell apoptosis (Fig-
ure 5F; Figure S5C), and inhibited cell
cycle progression (Figure 5G; Fig-
ure S5C). Furthermore, in the SMMC-
LTNM model, intratumoral injection of
cholesterol-conjugated PAK4 siRNA in-
hibited PAK4 expression (Figure 5A), sup-
pressed tumor growth, and reduced
serum AFP (Figure 5H). Additionally, inPAK4 stably overexpressed Hep3B cells, which transcribed
PAK4 mRNA without its 30 UTR, the induction of cell apoptosis
by miR-199a/b-3p restoration decreased as compared with
that in control cells (Figure 5I). These data confirm that the
antitumor effect of miR-199a/b-3p is mediated by inhibiting its
target PAK4.
miR-199a/b-3p Inhibits PAK4/Raf/MEK/ERK Pathway
in HCC
PAK4 was known to directly phosphorylate and activate Raf1
(Cammarano et al., 2005), and signaling through the Raf/MEK/
ERK cascade is well accepted to play critical prosurvival roles
in HCCdevelopment (Liu et al., 2006). Therefore, we investigated
whether Raf/MEK/ERK pathway was involved in the antitumor
effect of miR-199a/b-3p by targeting PAK4. We found that
overexpression of miR-199a/b-3p or knockdown of PAK4 in-
hibited the activation of Raf/MEK/ERK cascade in HCC both
in vivo and in vitro (Figure 5A; Figure S5D). Moreover, inhibition
of miR-199a/b-3p or overexpression of PAK4 also enhanced
the activation of Raf/MEK/ERK pathway in Hep3B cells
(Figure 5C). Thus, miR-199a/b-3p can inhibit PAK4/Raf/MEK/
ERK pathway to suppress HCC pathogenesis. Importantly, as
a single miRNA is likely to target multiple mRNAs (Selbach
et al., 2008), miR-199a/b-3p has also been shown to target
c-Met downstream signals and PI3K-mTOR pathway (Kim
et al., 2008; Fornari et al., 2010). In HCC, c-Met and mTOR
expression were also inhibited upon miR-199a/b-3p restoration
(Figure S5E). These pathways, well defined to participate in HCC
Figure 2. Histone Modifications Mediate Downregulation of
miR-199a/b-3p Expression in HCC
(A) Pri-miR-199a-1, pri-miR-199a-2, and pri-miR-199b expression were
detected by qRT-PCR in nonneoplastic liver tissues. Data are shown as
mean ± SD (n = 8). *, p < 0.05; **, p < 0.01.
(B) Pri-miR-199a-1 and pri-miR-199a-2 expressions were detected by qRT-
PCR in eight HCC samples and matched controls. Data are shown as in (A).
N, matched nonneoplastic control; T, HCC tissue.
(C) A schematic diagram shows the genomic context of miR-199a-1 and miR-
199a-2. Black and gray arrowheads represent miR-199a-3p and miR-199a-
5p, respectively. ChIP analysis for H3K4me3, H3K9me3, H3K27me3, and
H4K20me3 was done with two sets of primers spanning the reported genomic
regulatory regions (shown as filled and open bars).
(D) Real-time PCR analysis of H3K4me3, H3K9me3, and H3K27me3 at the
regulatory regions of miR-199a-1 and miR-199a-2 by ChIP assay in eight
HCC samples and matched controls. The primers are indicated in (C). Data
are shown as in (A).
See also Figure S2 and Table S10.
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miR-199a/b-3p in HCC progression.
DISCUSSION
In order to elucidate the deregulated miRNAs in cancer, several
methods, including microarray and qRT-PCR techniques, haveCbeen widely used in qualitative miRNA studies. These
approaches mainly focus on the alteration of individual miRNA
but lack vigor in revealing the abundance of each miRNA in the
background of the entire miRNome. Through these approaches,
a set of deregulated miRNAs have been revealed in HCC. As
miRNAs function mainly through repressing their targets expres-
sion, a minimum threshold amount must be reached for miRNAs
to exert their function (Brown et al., 2007; Sarasin-Filipowicz
et al., 2009). Thus, the abundantly expressed miRNAs seem to
be more important than those expressed at relatively low levels.
In-depth analysis of miRNome can reveal the expression level of
individual miRNA, especially its proportion in the entire
miRNome. Based on this approach, we found that only a few
miRNAs were abundantly expressed in human normal liver, but
they account for a large part of themiRNome.We do not exclude
the possibility that the poorly expressed miRNAs may also
participate in liver biology, but the abundant ones seem to be
prominent more obviously. For miR-122, the most abundant
miRNA in human liver, previous reports have shown its antitumor
effect in HCC (Kutay et al., 2006; Gramantieri et al., 2007;
Coulouarn et al., 2009). However, miR-122 expression was
found to be only decreased in about half of the HCC tissues
and less relevant to the survival of HCC patients in this study.
Hence, the roles ofmiR-122 in HCCcarcinogenesis and progres-
sion still need to be further evaluated, especially in the patients
with miR-122 decrement. For miR-192, the second most
abundant miRNA in human liver, its roles in liver biology and
the pathogenesis of liver diseases remain unknown. As to its
expression level in HCC, miR-192 does not seem to be signifi-
cantly deregulated in the HCC samples as we tested here. In
contrast to miR-122 and miR-192, miR-199a/b-3p, the third
most abundant miRNA in human liver, is decreased in a large
part of HCC tissue samples, thus providing clues for the future
study of its roles in HCC.
Identifying the molecular markers correlating with the survival
of cancer patients attractsmuch attention. For HCC, deregulated
expression of both coding genes and miRNAs has been sug-
gested to have considerable potential in predicting the prognosis
of HCC patients (Ji et al., 2009a). Here, miR-199a/b-3p is verified
to be frequently decreased in HCC tissues, and its decrement
significantly correlateswith the survival ofHCCpatients, outlining
a potential marker for predicting the prognosis of HCC patients.
Previous reports showed that deregulated miR-26 and miR-29
expression in HCC tissues also correlated with the survival of
HCC patients (Ji et al., 2009a; Xiong et al., 2010). Detecting the
expression level of these miRNAs, in combination with miR-
199a/b-3p and even other coding genes, may be valuable to
predict the prognosis of HCCpatientsmore accurately. Addition-
ally, as several other miRNAs, such as miR-99a, miR-125b-5p,
miR-100, and miR-143, are also suggested to be deregulated in
HCC tissues in this study, next we will determine whether dereg-
ulation of this panel of miRNAs also correlates with the survival of
HCC patients, and whether detecting all these miRNAs together
is more precise in identifying the prognosis of HCC patients.
As current chemotherapy for HCC is not effective, biological
therapy of HCC, including gene therapy and immunotherapy,
has been extensively investigated. In this study, the antitumor
effect of miR-199a/b-3p was determined both in vitro and
in vivo, suggesting its considerable potential in HCC geneancer Cell 19, 232–243, February 15, 2011 ª2011 Elsevier Inc. 237
Figure 3. miR-199a/b-3p Inhibits HCC Growth In Vitro
(A) miR-199a/b-3p expression in human normal liver, Hep3B, and SMMC-7721 HCC cell lines was detected using real-time qRT-PCR.
(B) Hep3B and SMMC-7721 HCC cells were transfected with miR-199a/b-3p mimics at a final concentration of 10 or 50 nM. miR-199a/b-3p expression was
detected using real-time qRT-PCR at 48 hr posttransfection. miR-199a/b-3p expression in human normal liver tissue was also shown as indicated.
(C–E) Hep3B and SMMC-7721 HCC cells were transfected as in (B). In the indicated time periods posttransfection, cell growth rate was evaluated using MTT
assay (C). Cells were stained using propidium iodide (PI) and Annexin V 72 hr posttransfection and analyzed by FACS. The Annexin V-positive cells were regarded
as apoptotic cells (D) and the cell cycle distribution was calculated (E).
(F and G) miR-199a/b-3p expression in Hep3B and SMMC-7721 HCC cells stably overexpressedmiR-199a/b-3p was detected using real-time qRT-PCR (F). The
cell growth rate of these cells was detected by MTT assay (G).
Data are shown as mean ± SD (n = 4) of one representative experiment. Similar results were obtained in three independent experiments. *, p < 0.05; **, p < 0.01.
See also Figure S3.
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miRNomes in Human Liver and HCCtherapy. The main obstacle for gene therapy is how to effectively
and safely deliver the genes into cancer cells or tumor microen-
vironment. As compared with other tissues, liver tissue is easier
to be targeted by both nonviral and viral delivery systems for
effector molecules and genes. Here, we used both cholesterol-
conjugated small RNAs and AAV8 delivery system, and
confirmed that both approaches could effectively restore
miR-199a/b-3p expression in HCC tissues of HCC-bearing
nude mice. Cholesterol-conjugated small RNAs are easier for
dose control, which are drug-like properties, but they can not
sustain the restoration of small RNAs for a long time period as
compared with viral delivery systems. AAV8 delivery system is238 Cancer Cell 19, 232–243, February 15, 2011 ª2011 Elsevier Inc.promising for liver-targeted gene therapy for its vector stability,
safety, and low immunogenicity, and it can sustain the gene
expression for a relative long time period. As reported, enforced
expression of miR-26a using AAV8 delivery system inhibited
tumorigenicity in mouse HCC model, also suggesting its
therapeutic potential (Kota et al., 2009). If combined with the en-
forced expression of other deregulated miRNAs, or even
together with coding genes bearing antitumor properties,
AAV8-mediated miR-199a/b-3p in vivo delivery may be more
promising in gene therapy for HCC.
Molecular mechanisms contributing to HCC pathogenesis
have been extensively investigated, and deregulated cell
Figure 4. miR-199a/b-3p Inhibits HCC Growth In Vivo
(A) Real-time qRT-PCR analysis of miR-122, miR-192, and miR-199a/b-3p expression in human normal liver tissue, SMMC-LTNM tumor tissue 72 hr after intra-
tumoral injection of cholesterol-conjugated miR-199a/b-3p mimics or control mimics.
(B and C) Effect of miR-199a/b-3p restoration on SMMC-LTNM tumor growth. Two weeks after subcutaneous inoculation of SMMC-LTNM tumor mass, HCC-
bearing nude mice were treated by intratumoral injection of cholesterol-conjugated miR-199a/b-3p mimics. Tumor volume and serum AFP were detected as
indicated in (B). H&E staining of HCC tissues was performed 2 weeks after intratumoral injection of cholesterol-conjugated miR-199a/b-3p mimics. Necrotic
area in HCC tissues was shown as indicated in (C). Scale bars, 50 mm.
(D–F) Effect of AAV8-miR-199a/b-3p administration on tumor growth of subcutaneous SMMC-LTNMmodel. One week after subcutaneous inoculation of SMMC-
LTNM tumor mass, AAV8-miR-199a/b-3p was intratumorally injected twice a week for 3 weeks. miR-122, miR-192, and miR-199a/b-3p expression in SMMC-
LTNM tumor tissue was detected by qRT-PCR (D). Tumor volume and serum AFP were detected as indicated in (E). H&E staining of HCC tissues was also per-
formed 3 weeks after AAV administration. Necrotic area and rare living tumor cell island (arrow) are shown as indicated in (F). Scale bars, 50 mm.
(G and H) One week after orthotopic inoculation of SMMC-LTNM tumor mass, AAV8-miR-199a/b-3p was delivered by a single tail vein injection of 1 3 1012 vg.
miR-122,miR-192, andmiR-199a/b-3p expression in orthotopic SMMC-LTNM tumor tissuewas detected 3weeks post AAV8-miR-199a/b-3p administration (G).
Tumor volume 3 weeks post AAV8-miR-199a/b-3p systemic administration was measured and serum AFP was detected as indicated in (H).
Data are shown as mean ± SD (n = 4) of one representative experiment. Similar results were obtained in three independent experiments. *, p < 0.05; **, p < 0.01.
See also Figure S4.
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miRNomes in Human Liver and HCCsignaling pathways, including MAPK, PI3K-mTOR, and Wnt-b-
Catenin pathways, have been found to play pivotal roles in HCC
carcinogenesis and progression. Among them, the activated
Raf/MEK/ERK signals are well-accepted prosurvival pathway inCHCC. The antitumor effect of miR-199a/b-3p is determined to
be mediated by inhibition of PAK4 and downstream ERK activa-
tion. Interestingly, during revision of this work, miR-199a-3p
was reported to inhibit HCC cell cycle progression in vitro byancer Cell 19, 232–243, February 15, 2011 ª2011 Elsevier Inc. 239
Figure 5. miR-199a/b-3p Inhibits PAK4/Raf/
MEK/ERK Pathway in HCC
(A) Hep3B cells were transfected as in (3B and 5E)
or HCC-bearing nude mice (SMMC-LTNM) were
treated as in (4B and 5H) as indicated. Expression
of b-actin (internal control), PAK4, phosphorylated
Raf, MEK, and ERK were detected by western
blot. Data are shown as a representative of three
independent experiments.
(B) HEK293 cells were cotransfected with empty
pMIR-Report firefly luciferase reporter plasmids
or PAK4 30 UTR firefly luciferase reporter plasmids,
pTK-Renilla-luciferase plasmids, together with
miR-199a/b-3p mimics as indicated. After 24 hr,
firefly luciferase activity was measured and
normalized by Renilla luciferase activity.
(C) Hep3B cells were transfected with miR-199a/
b-3p inhibitor as in (3B), or PAK4 expressing
plasmid as indicated. Expression of the indicated
proteins was detected by western blot as in (A).
(D) Expression of PAK4 and b-actin (internal
control) were detected by western blot in eight
available HCC protein samples. The patient
numbers were 25, 29, 32, 34, 35, 37, 39, and 40
in Table S4. N, matched nonneoplastic control;
T, HCC tissue.
(E–G) Hep3B HCC cells were transfected with
PAK4 siRNA as in (3B). Cell growth (E), apoptosis
(F), and cell cycle (G) were detected and analyzed
as in Figures 3C–3E.
(H) Effect of PAK4 knockdown on HCC tumor
growth in vivo. HCC-bearing nude mice SMMC-
LTNM were treated with intratumoral injection of
cholesterol-conjugated PAK4 siRNA as in Fig-
ure 4B). Tumor volume and serum AFP were de-
tected as indicated.
(I) Hep3B cells stably transfected with PAK4 ex-
pressing plasmid were transfected with miR-
199a/b-3p mimics as in (3B). Cell apoptosis was
detected and analyzed as in (3C).
Data are shown as mean ± SD (n = 4) of one
representative experiment. Similar results were
obtained in three independent experiments.
*, p < 0.05; **, p < 0.01.
See also Figure S5 and Table S11.
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miRNomes in Human Liver and HCCtargeting c-Met and mTOR expression (Fornari et al., 2010).
Indeed, a single miRNA has been thought to target multiple
mRNAs, named ‘‘targetome,’’ to regulate gene expression (Sel-
bach et al., 2008). In this study, c-Met andmTORwere also found
to be repressed in miR-199a/b-3p overexpressed Hep3B cells.
Previous reports showed that Hepatocyte growth factor (HGF)
may activate downstream PAK4 via PI3K-mTOR pathway
through receptor c-Met (Wells et al., 2002). Hence, major players
in this pathway may be tightly regulated by miR-199a/b-3p
expression in the liver, and miR-199a/b-3p restoration could
target c-Met/PI3K/PAK4/ERK pathway to repress HCC progres-
sion. However, there may be other molecules or signaling path-
ways which are also targeted by miR-199a/b-3p, and some of
them may be still unknown in HCC. This presumption may raise
interesting future work to reveal the entire functions of
miR-199a/b-3p in HCC carcinogenesis and progression.
ThemiRNomes of human normal liver, hepatitis liver, and HCC
have been presented in this study, providing resources for inves-240 Cancer Cell 19, 232–243, February 15, 2011 ª2011 Elsevier Inc.tigating the roles of miRNAs in liver biology and liver diseases.
Interestingly, no significant differencewas found among themiR-
Nomes of human normal liver, hepatitis liver, and nonneoplastic
liver tissues bearing HBV or HCV infection. It does not exclude
the possibility that miRNAs do not influence or participate in viral
infection and hepatitis. Maybe viral infection or liver inflammation
can only induce or repress the expression of some poorly ex-
pressed miRNAs, or the abundant miRNAs may also influence
the replication of hepatitis virus. Moreover, whether HBV or
HCVencode virus-derivedmiRNAs is also an important and inter-
esting topic remaining to be investigated in these miRNomes.EXPERIMENTAL PROCEDURES
Tissues and Cell Lines
Liver tissue samples were obtained from patients during operation, and the
details were shown in Tables S3, S4, S8, and S10. For survival analysis, four
independent cohorts of HCC patients from four different hospitals were
Cancer Cell
miRNomes in Human Liver and HCCused. They are Cohort 1, 142 HCC patients from Sun Yat-sen University
(Guangzhou, China); Cohort 2, 152 patients from Affiliated Tumor Hospital of
Guangxi Medical University (Nanning, China); Cohort 3, 102 HCC patients
from Eastern Hepatobiliary Surgery Hospital (Shanghai, China); and Cohort
4, 108 HCC patients from Zhongshan Hospital (Shanghai, China). Surgically
removed tissues were quickly frozen in liquid nitrogen until analysis. Human
normal liver tissues were obtained from distal normal liver tissue of liver
hemangioma patients. HBV infected liver tissue and severe chronic hepatitis
B liver tissue were obtained from distal liver tissue of the liver hemangioma
patients with HBV infection or severe chronic hepatitis B. HCC samples and
matched controls were obtained form HCC patients. All samples were
collected with the informed consent of the patients and the experiments
were approved by Institute Research Ethics Committee at Cancer Center,
Sun Yat-sen University; ethics committee of Guangxi Medical University;
ethics committee of Second Military Medical University; and Research ethics
committee at Liver Cancer Institute and Zhongshan Hospital, Fudan Univer-
sity. HEK293, Hep3B, SMMC-7721, Huh7, and HepG2 cell lines were obtained
and cultured as described previously (An et al., 2008; Wang et al., 2009c).
Illumina Solexa MPSS
Total RNA, containing miRNA, was extracted using miRNeasy Mini Kit
(QIAGEN 217004, Germany) and passed the RNA quality control for Solexa
sequencing. The sequencing procedure was described previously (Chen
et al., 2009). Sequencing data were mainly analyzed using SOAP (Short Oligo-
nucleotide Alignment Program) as described previously (Li et al., 2008). Clean
sequenced reads (excluding reads containing ambiguous base and adaptor
contaminants) (Table S1) yielded by Solexa sequencing were used for further
analysis. After removal of reads classified as small RNAs from rRNA etc. (rRNA,
tRNA, scRNA, snRNA, snoRNA), repeat-associated small RNAs, and mRNAs
(exons/introns) (Table S1), the sequenced reads of known miRNAs and each
individual of them, including small RNAs perfectly matching miRBase
precursor sequence and those identified as known miRNA editing polymor-
phisms (Ebhardt et al., 2009; Wu et al., 2007), were annotated and calculated.
Reagents
Antibodies specific to PAK4 (3242), phospho-Raf1 (9427), and phospho-MEK
(2354) were from Cell Signaling Technology (Danvers, MA). Antibodies specific
to phospho-ERK, phospho-p38, phospho-JNK, b-actin, and horseradish
peroxidase-coupled secondary antibodies were described previously (An
et al., 2008; Hou et al., 2009; Wang et al., 2009b). Cholesterol-conjugated
miR-199a/b-3p mimics and PAK4 siRNA for in vivo RNA delivery, miR-199a/
b-3p mimics and inhibitors for in vitro transfection, and their respective nega-
tive controls were from Ribobio Co. (Guangzhou, China) (Li et al., 2009).
RNA Quantification
Real-time qRT-PCR assay was performed as described previously (Hou et al.,
2009). For evaluating miRNA expression in each HCC tissue compared with its
matched control, miRNA level in tumor sample is divided by that in matched
nonneoplastic control (HCC/control). For pri-miR-199 assay, the detection
kits were from Applied Biosystems (Hs03302808_pri, Hs03302922_pri, and
Hs03302926_pri) (Carlsbad, CA). Other primers used were shown in Supple-
mental Experimental Procedures.
Bisulfate Sequencing
Genomic DNA was extracted, digested, purified, bisulfate converted and puri-
fied, PCR amplificated, cloned, and sequenced as reported (Kim et al., 2008).
ChIP Assay and Real-Time PCR
The cells were crosslinked and processed according to the Millipore (17-229)
Chromatin Immunoprecipitation (ChIP) Assay Kit (Temecula, CA) protocol.
Antibodies to H3K4me3 (Millipore 07-473), H3K9me3 (Millipore 05-1242),
H3K27me3 (Millipore 07-449), H4K20me3 (Abcam ab9053), or control IgG
(Santa Cruz sc-2027 or sc-2025) were used at 5 mg per immunoprecipitation
for the specific immunoprecipitation of respective histone residues. Tenmicro-
liters sonicated but preimmunoprecipitated DNA from each sample was used
as input controls. ChIP results were analyzed by real-time PCR as described
previously (Hou et al., 2009). The primers spanning the reported CpG islands
of miR-199a-1 and miR-199a-2 were shown in Supplemental ExperimentalCProcedures. Final results of each sample were normalized to the inputs.
Real-time PCR of GAPDH on the immunoprecipitated DNA fractions was per-
formed as additional internal controls (Ting et al., 2005).
Transfection
Hep3B cells (2 3 105) were seeded into each well of 6-well plates and incu-
bated overnight, and then transfected with RNAs or plasmids using
INTERFERin or jetPEI (Polyplus-transfection, France), respectively, as
described previously (Hou et al., 2009; Wang et al., 2009b).
In Vivo Assay
All animal experiments were undertaken in accordance with the National Insti-
tute of Health Guide for the Care and Use of Laboratory Animals, with the
approval of the Scientific Investigation Board of Second Military Medical
University, Shanghai. Human HCC-bearing male nude mice with subcuta-
neous passage of SMMC-LTNM were used for evaluating the antitumor effect
of miR-199a/b-3p in vivo. For preparation of subcutaneous model, 0.2 ml
grinded SMMC-LTNM tumor tissue was subcutaneously injected and inocu-
lated. For preparation of orthotopic HCC model, 0.02 ml grinded SMMC-
LTNM tumor tissue was directly injected and inoculated into the liver of nude
mice whose abdomen was surgically opened. For delivery of cholesterol-
conjugated RNA, 10 nmol RNA in 0.1 ml saline buffer was locally injected
into the tumor mass once every 3 days for 2 weeks. The rAAV (serotype 8)
vector expressing miR-199a/b-3p under promoter CAG was constructed as
previously described (Han et al., 2005). For AAV8 administration, 2 3 1011
vg AAV8 in 0.05 ml saline buffer was intratumorally injected into SMMC-
LTNM subcutaneous model twice a week for 3 weeks, or 1 3 1012 vg AVV8
in 0.2 ml saline buffer was injected through a single tail vein injection for
SMMC-LTNM orthotopic model. Tumor size was measured as described
previously (Qi et al., 2003). Serum AFP was detected using ELISA (Autobio,
Zhengzhou, China).
Statistical Analysis
Data are presented as mean ± SD. Statistical comparisons between experi-
mental groups were analyzed by Student’s t test and a two-tailed p < 0.05
was taken to indicate statistical significance. For analyzing survival of HCC
patients, log-rank test in SPSS 17.0 was used with the p values indicated.
Analysis of univariate or multivariate Cox proportional hazards regression
was also conducted using SPSS 17.0 with the hazard ratios and p values
indicated.
For information on the following, please see Supplemental Experimental
Procedures: 30 UTR luciferase reporter assay, RNA interference, MTT assay,
apoptosis assay, cell cycle analysis, western blot, and primers.
ACCESSION NUMBER
The Solexa sequencing data are available in GEO database (www.ncbi.nlm.
nih.gov/geo/) with accession number GSE21279.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and eleven tables and can be found with this article online at
doi:10.1016/j.ccr.2011.01.001.
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